228 related articles for article (PubMed ID: 33890870)
1. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
Nguyen H; Shah K; Waguespack SG; Hu MI; Habra MA; Cabanillas ME; Busaidy NL; Bassett R; Zhou S; Iyer PC; Simmons G; Kaya D; Pitteloud M; Subudhi SK; Diab A; Dadu R
Endocr Relat Cancer; 2021 Jun; 28(7):419-431. PubMed ID: 33890870
[TBL] [Abstract][Full Text] [Related]
2. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports.
Chen S; Ouyang L; Li L; Xiao Y; Wang S
Drug Discov Ther; 2024 Mar; 18(1):34-43. PubMed ID: 38382932
[TBL] [Abstract][Full Text] [Related]
4. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-mediated hypophysitis: no place like home.
Cooksley T; Knight T; Lindsay D; Gupta A; Ho JH; Higham C; Lorigan P; Adam S
Clin Med (Lond); 2023 Jan; 23(1):81-84. PubMed ID: 36697002
[TBL] [Abstract][Full Text] [Related]
6. Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists.
Druce I; Tawagi K; Shaw JLV; Ibrahim A; Lochnan H; Ong M
Curr Oncol; 2022 Jul; 29(7):4665-4677. PubMed ID: 35877230
[TBL] [Abstract][Full Text] [Related]
7. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
8. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.
Atkins P; Ur E
Endocr Res; 2020 Nov; 45(4):246-253. PubMed ID: 32892666
[TBL] [Abstract][Full Text] [Related]
9. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics of programmed cell death-1 inhibitor-associated hypophysitis].
Zhang Y; Wang SC; Zhang Q; Li HY; Liu SS; Wang XH; Liu Y
Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):192-197. PubMed ID: 38326046
[No Abstract] [Full Text] [Related]
11. The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature.
Urai S; Tomofuji S; Bando H; Kanzawa M; Yamamoto M; Fukuoka H; Tsuda M; Iguchi G; Ogawa W
J Neuroendocrinol; 2024 Jun; 36(6):e13395. PubMed ID: 38631695
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.
Jessel S; Weiss SA; Austin M; Mahajan A; Etts K; Zhang L; Aizenbud L; Perdigoto AL; Hurwitz M; Sznol M; Herold KC; Kluger HM
Front Oncol; 2022; 12():836859. PubMed ID: 35350573
[TBL] [Abstract][Full Text] [Related]
13. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
Kotwal A
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
[TBL] [Abstract][Full Text] [Related]
14. Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study.
Amylidi AL; Gogadis A; Yerolatsite M; Zarkavelis G; Torounidou N; Keramisanou V; Kampletsas E; Mauri D
Curr Oncol; 2023 Dec; 30(12):10509-10518. PubMed ID: 38132400
[TBL] [Abstract][Full Text] [Related]
15. Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors.
Heck A; Winge-Main AK
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34045201
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
20. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
